deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03259425

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)

Sponsor: Bristol-Myers Squibb

Conditions Melanoma
Interventions HF10 Nivolumab
Updated 14 times since 2017 Last updated: Jun 9, 2022 Started: Jan 3, 2018 Primary completion: Sep 21, 2018 Completion: Sep 25, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

DSMC Recommendation

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

Other Melanoma trials with similar outcome

Browse all Melanoma trials

This PHASE2 trial investigates Melanoma and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jul 2019 · 9 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2020 · 13 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Jul 2022 · 8 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jul 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Nov 2021 — Jul 2022 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Nov 2021 [monthly]

    Terminated PHASE2

▶ Show 9 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Nov 2019 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Oct 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  8. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Sep 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Takara Bio Inc.
  • University of Utah
Data source: University of Utah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations